• Judge temporarily blocks new Arkansas anti-abortion laws

Oliceridine studied for IV pain relief after abdominoplasty

Oliceridine studied for IV pain relief after abdominoplasty

(HealthDay)—Oliceridine is being proposed as an analgesic option for the relief of moderate-to-severe acute postoperative pain, according to a study recently published in Pain Practice.

Neil K. Singla, M.D., from Lotus Clinical Research in Pasadena, California, and colleagues randomly assigned 401 patients with moderate-to-severe acute postoperative pain following abdominoplasty to a loading dose of either placebo, oliceridine (1.5 mg), or morphine (4 mg), followed by demand doses administered through patient-controlled analgesia (0.1, 0.35, or 0.5 mg oliceridine; 1 mg morphine; or placebo) with a six-minute lockout interval.

The researchers found that effective analgesia was achieved with all oliceridine regimens, with responder rates of 61.0 percent for the 0.1-mg demand dose regimen, 76.3 percent for the 0.35-mg regimen, and 70.0 percent for the 0.5-mg regimen, versus 45.7 percent for placebo and 78.3 percent for morphine. Equivalent analgesic effect was seen for oliceridine 0.35- and 0.5-mg regimens, compared to morphine. The respiratory safety burden (RSB) demonstrated a dose-dependent increase across oliceridine regimens (mean hours, 0.1 mg: 0.43; 0.35 mg: 1.48; 0.5 mg: 1.59, compared to placebo [0.60]; the RSB measure for morphine was 1.72). There was also a dose-dependent increase in gastrointestinal adverse events across oliceridine demand dose regimens (0.1 mg: 49.4 percent; 0.35 mg: 65.8 percent; 0.5 mg: 78.8 percent, compared to placebo [47.0 percent] and morphine [79.3 percent]). However, the proportion of patients experiencing nausea or vomiting was lower with 0.35 and 0.5 mg oliceridine versus morphine.

“These findings support that oliceridine may provide a new treatment option for patients with moderate-to-severe acute pain where an intravenous opioid is warranted,” the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Trevena, which manufactures oliceridine and sponsored the study.


Leave a Reply

Your email address will not be published. Required fields are marked *